Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The science leader comes with a rich experience in the employment testing industry
Shaker is one of six receiving an individual award, which recognizes people, organizations and products bringing AI to life and applying it to solve real problems
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
Subscribe To Our Newsletter & Stay Updated
